- Home
- ALTO vs ENTX Comparison
ALTO vs ENTX Comparison
Compare ALTO & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALTO
- ENTX
- Stock Information
- Founded
- ALTO 2003
- ENTX 2010
- Country
- ALTO United States
- ENTX Israel
- Employees
- ALTO N/A
- ENTX N/A
- Industry
- ALTO Major Chemicals
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALTO Industrials
- ENTX Health Care
- Exchange
- ALTO Nasdaq
- ENTX Nasdaq
- Market Cap
- ALTO 90.6M
- ENTX 106.4M
- IPO Year
- ALTO N/A
- ENTX 2018
- Fundamental
- Price
- ALTO $1.06
- ENTX $2.55
- Analyst Decision
- ALTO Strong Buy
- ENTX Strong Buy
- Analyst Count
- ALTO 1
- ENTX 1
- Target Price
- ALTO $5.50
- ENTX $10.00
- AVG Volume (30 Days)
- ALTO 247.9K
- ENTX 280.4K
- Earning Date
- ALTO 11-06-2025
- ENTX 11-07-2025
- Dividend Yield
- ALTO N/A
- ENTX N/A
- EPS Growth
- ALTO N/A
- ENTX N/A
- EPS
- ALTO N/A
- ENTX N/A
- Revenue
- ALTO $933,137,000.00
- ENTX $166,000.00
- Revenue This Year
- ALTO N/A
- ENTX N/A
- Revenue Next Year
- ALTO $7.53
- ENTX N/A
- P/E Ratio
- ALTO N/A
- ENTX N/A
- Revenue Growth
- ALTO N/A
- ENTX 191.23
- 52 Week Low
- ALTO $0.76
- ENTX $1.50
- 52 Week High
- ALTO $2.05
- ENTX $2.95
- Technical
- Relative Strength Index (RSI)
- ALTO 45.48
- ENTX 62.46
- Support Level
- ALTO $1.05
- ENTX $2.12
- Resistance Level
- ALTO $1.12
- ENTX $2.43
- Average True Range (ATR)
- ALTO 0.05
- ENTX 0.22
- MACD
- ALTO -0.01
- ENTX 0.00
- Stochastic Oscillator
- ALTO 6.25
- ENTX 51.81
About ALTO Alto Ingredients Inc.
Alto Ingredients Inc is a producer of specialty alcohols and essential ingredients. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include food and beverage companies and consumer products manufacturers and distributors. The company operates under three segments: Marketing and distribution, Pekin Campus production, Western production, and Others.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.